Based on preclinical evidence suggesting that chemotherapy and radiotherapy may up-regulate PD-L1 expression in tumor cells, durvalumab may provide clinical benefit after chemoradiotherapy in unresectable stage III NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.